| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | neural apoptosis-regulated proteinase 1 |
| Clinical data | |
| Other names | RN317 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6422H9922N1730O2012S54 |
| Molar mass | 145289.36 g·mol−1 |
Ralpancizumab (INN;[1] development code RN317) is a monoclonal antibody designed for the treatment of dyslipidemia.[2][3]
This drug was developed by Pfizer.
References
[edit]- ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
- ^ "Ralpancizumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association..
- ^ Levisetti M, Joh T, Wan H, Liang H, Forgues P, Gumbiner B, Garzone PD (January 2017). "A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy". Clinical and Translational Science. 10 (1): 3–11. doi:10.1111/cts.12430. PMC 5351011. PMID 27860267.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |